Logo
B

Bloom Science, Inc.

20 employees

Bloom Science is a clinical-stage, central nervous system (CNS) company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs in Dravet syndrome; other rare epilepsies; Amyotrophic Lateral Sclerosis (ALS), a disease that causes nerve cells to die, which breaks the neural pathways, and causes extreme mobility loss over time; and neurodegenerative and cognitive disorders. At Bloom Science we balance fun with the serious business of changing lives. We have a values-driven culture that is built from the ground up. We empower our team members to treat every clinical trial like a patient’s life depends on it – because it does. Our leaders are in the trenches with you - committed to advancing science and moving mountains for a potentially transformational approach to medicine. For more information, visit https://bloomscience.com/

Investor insights

Funding rounds participated in

$12M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2018

Funding rounds raised

Total raised

$12M

from 3 investors over 1 rounds

B

Bloom Science, Inc. raised $12M on January 9, 2022

Investors: Leaps by Bayer, ALS Investment Fund and + 2 Other investors

FAQ